# Compass Therapeutics to Participate in Upcoming May Investor Events Canonical URL: https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121 Ticker: CMPX Company: Compass Therapeutics Source: Compass Therapeutics Published: 2026-05-12 11:30 EST ## Summary Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company... ## Article Body Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 19, 2026 Time: 1:30 PM ET Webcast Link: https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f 2026 Stifel Virtual Targeted Oncology Forum Date: Wednesday, May 20, 2026 Time: 11:30 AM ET Webcast Link: https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6 Virtual/Replay availability: Presentations will be archived on Compass’ Events page. Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings. About Compass Therapeutics Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com . Investor Contact ir@compasstherapeutics.com Media Contact Anna Gifford, Chief of Staff media@compasstherapeutics.com 617-500-8099 ## Recent Company News - 2026-07-17 14:42 EST — [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60) — Source: Compass Therapeutics - 2026-05-28 11:30 EST — [Compass Therapeutics to Participate in Upcoming June Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840) — Source: Compass Therapeutics - 2026-05-21 21:00 EST — [Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911) — Source: Compass Therapeutics - 2026-05-12 11:30 EST — [Compass Therapeutics to Participate in Upcoming May Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121) — Source: Compass Therapeutics - 2026-05-05 11:30 EST — [Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-c-7bfdf19a) — Source: Compass Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)